Aguilar E A, Robbins K T, Stephens J, Dimery I W, Batsakis J G
Am J Clin Oncol. 1987 Feb;10(1):26-32. doi: 10.1097/00000421-198702000-00006.
The aggressiveness of small (oat) cell carcinoma of the larynx presents a therapeutic challenge to the oncologist. Since the first description of this type of carcinoma in 1972, 52 patients have been reported in the literature and a variety of treatment regimens have been used. The purpose of this study was to report two new cases and review all previous reports to determine the disease's biological behavior, clinical manifestations, and optimum treatment. Thirty-five percent of the tumors were transglottic, and 27% were supraglottic. Fifty-four percent of patients had regional metastases at initial presentation and 17.6% had distant metastases. The median survival was 10 months for all patients. Patients who were treated with chemotherapy with or without other modalities had the best 2-year survival rates (52.2%). Forty-one percent of patients had regional recurrence only, 12.5% had regional recurrence and distant metastases, and 2% developed distant metastases only. We conclude that patients with oat cell carcinoma of the larynx should be treated with combination chemotherapy and radiation therapy. Surgery is best reserved for persistent and recurrent disease at the primary site and neck.
喉小（燕麦）细胞癌的侵袭性给肿瘤学家带来了治疗挑战。自1972年首次描述这种类型的癌以来，文献中已报道了52例患者，并使用了多种治疗方案。本研究的目的是报告两例新病例并回顾所有既往报告，以确定该疾病的生物学行为、临床表现和最佳治疗方法。35%的肿瘤为跨声门型，27%为声门上型。54%的患者初诊时出现区域转移，17.6%有远处转移。所有患者的中位生存期为10个月。接受化疗（无论是否联合其他方式）治疗的患者2年生存率最佳（52.2%）。41%的患者仅出现区域复发，12.5%的患者出现区域复发和远处转移，2%的患者仅发生远处转移。我们得出结论，喉燕麦细胞癌患者应接受联合化疗和放射治疗。手术最好保留用于原发部位和颈部的持续性和复发性疾病。
